Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in several upcoming investor conferences. The schedule includes a presentation at the Stifel 2020 Virtual Healthcare Conference on November 16 at 4:40 p.m. ET, and virtual 1x1 meetings at both the 11th Annual Craig-Hallum Alpha Select Conference on November 17 and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19. Additionally, a fireside chat will take place at the 32nd Annual Piper Sandler Healthcare Conference from December 1 to 3. Webcasts of these events will be accessible on the Apyx investor relations website.
Apyx Medical Corporation (NASDAQ:APYX) announced the publication of two peer-reviewed articles in Dermatological Reviews, enhancing the clinical evidence for its Renuvion Helium Plasma Technology. The first article discusses Renuvion’s effectiveness for subdermal neck coagulation, while the second focuses on its safety and efficacy following liposuction in various anatomical areas. These publications aim to strengthen the product's risk/benefit profile and support broader market adoption.
Apyx Medical Corporation (NASDAQ:APYX), known for its Helium Plasma Technology, will release its third quarter fiscal results on November 9, 2020, before market opening. A conference call will follow at 8:00 a.m. ET for discussion and Q&A. Interested callers should dial 877-407-8289 (international: 201-689-8341) with access code 13711022. A webcast will also be available on their Investor Relations website. The company focuses on innovative solutions in cosmetic and surgical markets, with Renuvion® and J-Plasma® technology enhancing surgical precision and outcomes.